China’s generative artificial intelligence (AI)-driven biotech firm Insilico Medicine has entered into a partnership with compatriot firm invoX Pharma, a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177). The collaboration aims to combine Insilico’s AI and computer-aided drug discovery expertise, including its proprietary PandaOmics target discovery engine, with invoX’s innovative drug development and data science capabilities to expand potential indications for anti-tumor pipelines.
The partnership will see both parties training large AI model groups for multiple tasks, aiming for platform-level collaborative innovation. The AI models developed through this collaboration will undergo validation through a series of practical applications. Already, two projects are progressing rapidly, with more innovative projects and real-world cases expected to be supported in the future.- Flcube.com
